Navigation Links
Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit
Date:7/9/2008

Renowned oncology researcher Dr. Daniel Von Hoff, a member of President Bush's National Cancer Advisory Board, provides an in-depth look at "The Complete Phase Ib," an oncology clinical trial design that creates rapid accrual rates, substantial economies of scale, significant time savings, enthusiasm from investigators and patients, and improved therapeutic benefits. The complete interview is available for download from Medelis, a contract research organization providing complete oncology clinical trial design, management and execution.

Phoenix, AZ (PRWEB) July 9, 2008 -- Medelis, Inc., a contract research organization providing complete oncology clinical trial design, management and execution, today published a free new downloadable abstract, "The Complete Phase Ib: An Approach to Getting to Phase II Faster", an interview with renowned oncology investigator Daniel Von Hoff, M.D.

In the interview, Dr. Von Hoff discusses "The Complete Phase Ib", a trial design that streamlines phase I by testing various drug combinations in one trial with multiple arms running in parallel. This structure creates rapid accrual rates, substantial economies of scale and significant time savings for sponsors versus the traditional sequential approach. It also garners enthusiasm from investigators and patients, who ultimately gain greater potential for improved therapeutic benefits and care.

Dr. Von Hoff provides insight and details on a variety of questions about this approach:

  • The phase Ib concept
  • Patient accrual and treatment benefits
  • How the approach can "rescue" patients
  • Dosing strategies
  • Logistical considerations
  • Cost and timing considerations
  • Effects on phase II studies
  • Reactions from the FDA, investigators, sponsors and patients

A member of President Bush's National Cancer Advisory Board, Dr. Von Hoff's major interest is in the development of new anticancer agents both in the clinic and in the laboratory. His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies with a focus on pancreatic cancer.

Dr. Von Hoff currently serves as Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He also serves as Chief Scientific Officer for U.S. Oncology and the Scottsdale Clinical Research Institute and is a founding shareholder and advisory board member of Medelis.

The abstract is the second in Medelis' complimentary "Peer Perspectives in Oncology" Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today: rising costs, optimum patient accrual, targeted therapeutics, patient safety, FDA regulations, efficacy, budgets, and timelines.

The abstract is available for download in the Insider Abstracts section of Medelis' Web site.

About Medelis, Inc.:
Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, clinical trial management physicians and advisory board members, including Dan Von Hoff, James Gourzis, Howard Burris and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Offerings include strategic plans for regulatory approval from phase I through NDA and complete oncology clinical trial design, management and execution.

Medelis is privately-held and located in Phoenix, Arizona with locations in Nashville, Phoenix and Reno.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
2. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
3. HealthSouth Finalizes Sale of Corporate Campus to Daniel Corporation
4. Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
7. Vincent Corso and Daniel Trush Win 2007 Avis We Try Harder Awards
8. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
9. Derma Sciences CEO ED Quilty Discusses Company on BNN
10. PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors
11. PAHEF Discusses Neglected Diseases and Disaster Preparedness with Innovative Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Sourced from the ... some unique properties including its unmatched natural purity of just 6 ppm TDS (Total ... crisp. , Nothing Water has been available in several ShopRite and FoodTown stores in ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... care journeys, announced today that it has raised $6.0 million in an initial ... by Clarify Health’s conviction that patients and their caregivers can receive far better ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of the "Global ... report to their offering. ... , The global ultrasound device market ... to grow at a CAGR of 5.5% during 2016-2022. Based on portability, ... forecast period, a CAGR of 8.8% in the global market. Among the ...
(Date:12/2/2016)... ATLANTA , Dec. 2, 2016 Quantum ... screening and expert radiologist interpretation directly to women at ... partners with corporations, such as Delta Air Lines and ... cancer screening as a component of wellness initiatives. ... women of SunTrust. It enables them to have a ...
(Date:12/2/2016)... 2016 In the first ever attempt to ... derived from C. sativa, the Hebrew University in Jerusalem, ... Federico II , the Universita` del Piemonte Orientale and ... integrated and unified inventory of phytocannabinoids of different botanical ... the remarkable chemical and structural diversity of phytocannabinoids. As ...
Breaking Medicine Technology: